Related Experiment Videos
Tacrolimus 0.1% ointment for seborrhoeic dermatitis: an open-label pilot study
T J Braza1, J B DiCarlo, S L Soon
1Department of Dermatology, Emory University School of Medicine, Atlanta, GA, USA.
The British Journal of Dermatology
|June 28, 2003
Summary
Topical tacrolimus 0.1% ointment shows promise for treating seborrhoeic dermatitis, offering an alternative to corticosteroids. This pilot study found it safe and effective for short-term use in patients with this common skin condition.
Area of Science:
- Dermatology
- Immunosuppression
- Pharmacology
Background:
- Seborrhoeic dermatitis is a common inflammatory skin condition.
- Topical corticosteroids are frequently used but carry risks with long-term application.
- Tacrolimus, a topical immunosuppressant, presents a potential alternative treatment option.
Purpose of the Study:
- To evaluate the safety and efficacy of topical tacrolimus 0.1% ointment.
- To assess its potential as a treatment for seborrhoeic dermatitis.
Main Methods:
- An open-label, uncontrolled 6-week trial involving 16 subjects with seborrhoeic dermatitis.
- Daily application of topical tacrolimus 0.1% ointment after a 2-week washout period.
- Assessment of erythema, scaling, and global assessments at baseline, week 2, and week 6.
Main Results:
- Significant improvements in erythema and scaling scores were observed by week 6 (P < 0.05).
- Investigator and subject global assessments showed marked improvement, indicating treatment efficacy.
- Only mild, transient side effects like application site pruritus/burning were reported in two subjects.
Conclusions:
- Topical tacrolimus 0.1% ointment demonstrated short-term efficacy in treating seborrhoeic dermatitis.
- The treatment was well-tolerated with minimal adverse events.
- Further controlled trials are recommended to confirm efficacy and safety for seborrhoeic dermatitis.